US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polaryx Therapeutics Inc

2.04

-0.1000-4.67%

Post-market: 2.040.00000.00%19:30 EDT

Volume:81.51K

Turnover:168.49K

Market Cap:101.69M

PE:-14.89

High:2.21

Open:2.09

Low:2.02

Close:2.14

52wk High:48.91

52wk Low:1.85

Shares:49.85M

Float Shares:6.78M

Volume Ratio:3.63

T/O Rate:1.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1370

EPS(LYR):-0.1978

ROE:-96.56%

ROA:-42.52%

PB:9.30

PE(LYR):-10.31

Loading ...

Overview Company News Filings

Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase

BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing

Polaryx Therapeutics closes USD 10 million PIPE offering of 2,502,696 shares at USD 4 each

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of Soteria Phase 2 Basket Trial

THOMSON REUTERS

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Polaryx net loss narrows to $2.54 million in Q1 FY26

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI

BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug

Polaryx receives U.S. FDA Fast Track Designation for PLX-200

Polaryx Therapeutics, Inc - to Initiate Soteria Phase 2 Trial in Second Half of 2026

THOMSON REUTERS

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics to present at Needham Virtual Healthcare Conference

Polaryx FY2025 net loss narrows 70.4% to USD 9 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PLYX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":2.04,"timestamp":1789761600000,"preClose":2.14,"halted":0,"volume":81507,"hourTrading":{"tag":"盘后","latestPrice":2.04,"preClose":2.04,"latestTime":"19:30 EDT","volume":1278,"amount":2611.02,"timestamp":1789774205655,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04672897196261686,"floatShares":6777800,"shares":49846000,"eps":-0.137,"marketStatus":"Market Closed","change":-0.1,"latestTime":"09-18 16:00:00 EDT","open":2.09,"high":2.205,"low":2.02,"amount":168487.358064,"amplitude":0.086449,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.137,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.1139,"preClose":2.14,"latestTime":"07:25 EDT","volume":50,"amount":105.69500000000001,"timestamp":1789730744246,"change":-0.0261,"changeRate":-0.012196,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.04,"preClose":2.04,"latestTime":"19:30 EDT","volume":1278,"amount":2611.02,"timestamp":1789774205655,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.6300515427636886},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":6777800,"roa":"-42.52%","roe":"-96.56%","lyrEps":-0.197809,"volumeRatio":3.6300515427636886,"shares":49846000,"dividePrice":0,"high":2.205,"amplitude":0.086449,"preClose":2.14,"low":2.02,"week52Low":1.85,"pbRate":"9.30","week52High":48.91,"institutionHeld":0,"latestPrice":2.04,"eps":-0.137,"divideRate":0,"volume":81507,"delay":0,"ttmEps":-0.137,"open":2.09,"prevYearClose":45,"prevWeekClose":2.01,"prevMonthClose":2.01,"prevQuarterClose":2.66,"fiveDayClose":2.01,"twentyDayClose":2.14,"sixtyDayClose":2.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PLYX","fiscalQuarterEnding":"2026/06","expectedEps":-0.05,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-09-18","current":-14.890511,"percent":0.803797,"low":-201.755192,"twenty":-30.213296,"median":-17.981243,"eighty":-15.659028,"high":-13.609579,"avg":-24.762393,"sd":20.951564,"marketCap":106670425},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427},{"date":"2026-02-20","current":-15.391039,"twenty":-99.090622,"median":-34.183094,"eighty":-16.79756,"marketCap":126406602},{"date":"2026-02-27","current":-18.388545,"twenty":-65.483971,"median":-21.847205,"eighty":-15.852193,"marketCap":151025117},{"date":"2026-03-06","current":-15.102817,"twenty":-58.797227,"median":-17.581524,"eighty":-15.852193,"marketCap":124039438},{"date":"2026-03-13","current":-26.804618,"twenty":-52.848332,"median":-19.339676,"eighty":-15.932895,"marketCap":220146331},{"date":"2026-03-20","current":-32.569052,"twenty":-39.601662,"median":-22.827159,"eighty":-16.059713,"marketCap":267489628},{"date":"2026-03-27","current":-33.617166,"twenty":-34.863297,"median":-29.312147,"eighty":-16.128886,"marketCap":302050234},{"date":"2026-04-02","current":-40.045527,"twenty":-39.919067,"median":-31.906143,"eighty":-16.140415,"marketCap":359809057},{"date":"2026-04-10","current":-30.350294,"twenty":-38.506935,"median":-31.819676,"eighty":-16.417108,"marketCap":272697390},{"date":"2026-04-17","current":-33.669857,"twenty":-37.045768,"median":-31.906143,"eighty":-16.636156,"marketCap":302523667},{"date":"2026-04-24","current":-28.031869,"twenty":-35.562162,"median":-31.819676,"eighty":-16.762974,"marketCap":251866340},{"date":"2026-05-01","current":-27.663028,"twenty":-34.579831,"median":-30.218565,"eighty":-17.281773,"marketCap":248552309},{"date":"2026-05-08","current":-20.128146,"twenty":-34.275325,"median":-29.928762,"eighty":-18.065737,"marketCap":180851394},{"date":"2026-05-15","current":-17.967795,"twenty":-34.128071,"median":-28.532438,"eighty":-17.67102,"marketCap":161440642},{"date":"2026-05-22","current":-28.799226,"twenty":-34.059774,"median":-27.768411,"eighty":-17.809721,"marketCap":186532590},{"date":"2026-05-29","current":-22.293817,"twenty":-33.996545,"median":-27.504954,"eighty":-17.904565,"marketCap":144397055},{"date":"2026-06-05","current":-18.492904,"twenty":-33.827932,"median":-26.891329,"eighty":-18.119363,"marketCap":119778541},{"date":"2026-06-12","current":-17.396487,"twenty":-33.648781,"median":-26.314014,"eighty":-17.641188,"marketCap":112677046},{"date":"2026-06-18","current":-16.884826,"twenty":-33.534361,"median":-25.713443,"eighty":-17.290923,"marketCap":109363016},{"date":"2026-06-26","current":-16.884826,"twenty":-33.180562,"median":-24.313934,"eighty":-17.139848,"marketCap":109363016},{"date":"2026-07-02","current":-18.858377,"twenty":-33.090251,"median":-23.364528,"eighty":-17.282806,"marketCap":122145706},{"date":"2026-07-10","current":-17.761959,"twenty":-32.741985,"median":-22.293817,"eighty":-17.323392,"marketCap":115044211},{"date":"2026-07-17","current":-16.884826,"twenty":-32.569052,"median":-20.503003,"eighty":-17.031015,"marketCap":109363016},{"date":"2026-07-24","current":-15.422936,"twenty":-32.510645,"median":-20.174077,"eighty":-16.884826,"marketCap":99894356},{"date":"2026-07-31","current":-15.715314,"twenty":-32.46514,"median":-20.022763,"eighty":-16.813445,"marketCap":101788088},{"date":"2026-08-07","current":-16.226975,"twenty":-32.288502,"median":-19.406585,"eighty":-16.664276,"marketCap":105102119},{"date":"2026-08-14","current":-18.273621,"twenty":-31.997409,"median":-19.285083,"eighty":-16.519353,"marketCap":118358242},{"date":"2026-08-21","current":-15.574598,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"marketCap":106670425},{"date":"2026-08-28","current":-15.356263,"twenty":-31.831205,"median":-18.492904,"eighty":-16.285451,"marketCap":105175045},{"date":"2026-09-04","current":-14.482921,"twenty":-30.64417,"median":-18.456357,"eighty":-16.082374,"marketCap":99193526},{"date":"2026-09-11","current":-14.482921,"twenty":-30.287064,"median":-18.36763,"eighty":-15.991608,"marketCap":99193526},{"date":"2026-09-18","current":-15.574598,"twenty":-30.213296,"median":-17.981243,"eighty":-15.659028,"marketCap":106670425}],"updateTime":1789892296008},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639161213","title":"Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2639161213","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639161213?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:01","pubTimestamp":1780012880,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics disclosed an increase in beneficial ownership tied to Mstone Partners Healthcare, which bought 88,453 common shares at USD 4.07.Alex Keun Mo Yang, chief executive officer, was listed as an indirect beneficial owner through Mstone Partners Healthcare.The filing showed 24,233,249 common shares beneficially owned following the purchase.The transaction value was USD 360,000 in gross proceeds to the issuer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL64dvV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693779","title":"BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693779?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:37","pubTimestamp":1779971824,"startTime":"0","endTime":"0","summary":"BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity FinancingMay 28 (Reuters) - Polaryx Therapeutics, Inc PLYX.O:ANNOUNCES CLOSING OF $10 MILLION PRIVATE PLACEMENT EQUITY FINANCING ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN425108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693477","title":"Polaryx Therapeutics closes USD 10 million PIPE offering of 2,502,696 shares at USD 4 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693477?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:31","pubTimestamp":1779971496,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics closed a $10 million PIPE on May 28, 2026 through an unregistered sale of common stock.Investors bought 2,502,696 shares at an average price of about $4 per share.Proceeds earmarked for the Phase 2 SOTERIA basket trial of PLX-200, ongoing R&D, working capital, general corporate purposes.Financing expected to extend operating runway into the second quarter of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLbfzWjj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","IE00BKPKM429.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4007","SG9999014013.SGD","LU2095319765.USD","BK4588","SG9999014005.SGD","BK4585","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469313","title":"Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of Soteria Phase 2 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469313?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA64Y6TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693224","title":"Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693224","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971400,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, May  28, 2026  (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying thera","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302836/0/en/Polaryx-Therapeutics-Announces-Closing-of-10-Million-Private-Placement-Equity-Financing-to-Support-Launch-of-SOTERIA-Phase-2-Basket-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4215","BK4588","EQR","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635808870","title":"Polaryx net loss narrows to $2.54 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635808870?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:13","pubTimestamp":1778840018,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics reported a net loss of $2.54 million for the three months ended March 31, 2026, narrowing from a $5.05 million loss a year earlier.Operating loss narrowed to $1.96 million from $5.05 million, as operating expenses fell to $1.96 million from $5.05 million.Research and development expense dropped to $679,000 from $4.72 million, while general and administrative expense climbed to $1.28 million from $336,000.Other expense related to direct listing offering costs was $586,000 versus none a year earlier; cash and cash equivalents totaled $3.08 million at quarter-end.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4pLD28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635574894","title":"Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574894","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635574894?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:15","pubTimestamp":1778764500,"startTime":"0","endTime":"0","summary":"Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award WinnerPARAMUS, NJ, May  14, 2026  (GLOBE NEWSWIRE) -- Pol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295060/0/en/Polaryx-Therapeutics-Receives-GHP-Magazine-s-Healthcare-Pharmaceuticals-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","BK4007","HCSG","LABU","BK4588","BK4581","LU0128526141.USD","PLYX","LU0029874061.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629496831","title":"Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2629496831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629496831?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:30","pubTimestamp":1776947400,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, April  23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279922/0/en/Polaryx-Therapeutics-to-Participate-in-National-Tay-Sachs-Allied-Diseases-Association-Annual-Family-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007","NHLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629605562","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI","url":"https://stock-news.laohu8.com/highlight/detail?id=2629605562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629605562?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:49","pubTimestamp":1776786546,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCIWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL6N414143:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APD","DGX","GE","INTW","CE","MVLL","MSCI","HAL","ALK","CVS","AMZU","MACW.SI","RTX","HUM","PBI","CNC","FRMI","MRVL","ELV","SPRB","CRML","NTRS","ECL","DHR","AXTI","RDTL","TER","AAPB","AAPU","AAPL","INTC","AMZD","PLYX","UNH","DHI","CRMX","RDDT","AAPD","AAPX","SHW","HL","HLXX","CDE","TSCO","AMZP","MMM","AMZN","TERG","ALAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629034752","title":"BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2629034752","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629034752?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:11","pubTimestamp":1776777102,"startTime":"0","endTime":"0","summary":"BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug** Shares of drug developer Polaryx Therapeutics PLYX.O rise 4.76% to $5.97 premarket** Company says the U.S. FDA has granted fast-track status to its experimental drug, PLX-200, for CLN3 disease, Krabbe disease and Sandhoff disease — three rare genetic disorders that damage the nervous system** FDA's fast-track tag is meant to speed up development and review of treatments for serious diseases with unmet medical needs** With the fast-track grant it received in March for CLN2 disease, PLX-200 now has the designation for all four disorders planned for its next study - PLYX** Company plans to start a mid-stage study in the second half of 2026, testing PLX-200 across all four disorders in the United States, Europe and Asia** PLYX shares down 83.7% since their IPO in February  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL4N41419E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603469","title":"Polaryx receives U.S. FDA Fast Track Designation for PLX-200","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603469?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:59","pubTimestamp":1776776395,"startTime":"0","endTime":"0","summary":"Polaryx (PLYX) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to PLX-200 for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-receives-u-s-fda-fast-track-designation-for-plx-200-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-receives-u-s-fda-fast-track-designation-for-plx-200-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","PLX","LABU","PLYX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629392740","title":"Polaryx Therapeutics, Inc - to Initiate Soteria Phase 2 Trial in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629392740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629392740?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUABY5R7Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629039015","title":"Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629039015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629039015?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774600,"startTime":"0","endTime":"0","summary":"PARAMUS, N.J., April  21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, tod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277945/0/en/Polaryx-Therapeutics-Receives-U-S-FDA-Fast-Track-Designations-for-All-Four-Indications-to-be-Evaluated-in-the-SOTERIA-Basket-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","HSCT","BK4007","PLYX","BBB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627280357","title":"Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2627280357","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627280357?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:15","pubTimestamp":1776258900,"startTime":"0","endTime":"0","summary":"Company selected as a Diamond honoree for Excellence in Pediatric CarePARAMUS, NJ, April  15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focus","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274544/0/en/Polaryx-Therapeutics-Recognized-with-Pinnacle-Award-for-Excellence-in-Pediatric-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515627","title":"Polaryx Therapeutics to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515627","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515627?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:31","pubTimestamp":1775046700,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics will take part in Needham Virtual Healthcare Conference April 13-16, 2026.Group presentation set for April 16, 2026 at 10:15 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1xrQbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4585","BK4007","SG9999014005.SGD","LU2210149790.SGD","LU2210150020.SGD","NDAQ","BK4588","PLYX","SG9999014013.SGD","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621916063","title":"Polaryx FY2025 net loss narrows 70.4% to USD 9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621916063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621916063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:01","pubTimestamp":1774346515,"startTime":"0","endTime":"0","summary":"Polaryx published its annual report  reporting a net loss and comprehensive loss of USD 9.0 million and an operating loss of USD 7.8 million.Research and development expenses rose more than doubled to USD 6.3 million, driven mainly by consulting costs, work under the Rush MSA, CRO services, and stock-based compensation tied to shares issued for an exclusive gene therapy patent license.General and administrative expenses were USD 1.6 million.Cash and cash equivalents were USD 5.1 million, and Polaryx said this is expected to fund operations through the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9zbyzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}